192 related articles for article (PubMed ID: 17340994)
41. Quercus infectoria: a candidate for the control of methicillin-resistant Staphylococcus aureus infections.
Chusri S; Voravuthikunchai SP
Phytother Res; 2008 Apr; 22(4):560-2. PubMed ID: 18338770
[TBL] [Abstract][Full Text] [Related]
42. [Bacteriophage types of methicillin--resistant Staphylococcus aureus strains isolated in 2005-2006 in the Gdańsk area and their resistance to other antibiotics].
Wiśniewska K; Garbacz K; Piechowicz L
Med Dosw Mikrobiol; 2007; 59(4):279-85. PubMed ID: 18416119
[TBL] [Abstract][Full Text] [Related]
43. In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
Qadri SM; Ueno Y; Abu Mostafa FM; Halim M
Chemotherapy; 1997; 43(2):94-9. PubMed ID: 9084917
[TBL] [Abstract][Full Text] [Related]
44. Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.
Calatayud L; Ardanuy C; Cercenado E; Fenoll A; Bouza E; Pallares R; Martín R; Liñares J
Antimicrob Agents Chemother; 2007 Sep; 51(9):3240-6. PubMed ID: 17606677
[TBL] [Abstract][Full Text] [Related]
45. In vitro susceptibility and resistance of animal staphylococci to macrolide antibiotics and related compounds.
Devriese LA
Ann Rech Vet; 1976; 7(1):65-74. PubMed ID: 136223
[TBL] [Abstract][Full Text] [Related]
46. Subinhibitory quinupristin/dalfopristin attenuates virulence of Staphylococcus aureus.
Koszczol C; Bernardo K; Krönke M; Krut O
J Antimicrob Chemother; 2006 Sep; 58(3):564-74. PubMed ID: 16895938
[TBL] [Abstract][Full Text] [Related]
47. In vitro activity of quinupristin/dalfopristin against clinical isolates of common gram-positive bacteria in Taiwan.
Chang SC; Fang CT; Hsueh PR; Luh KT; Hsieh WC
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):299-303. PubMed ID: 10212757
[TBL] [Abstract][Full Text] [Related]
48. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
49. Activity of quinupristin/dalfopristin and its components against Haemophilus influenzae.
Jorgensen JH; McElmeel ML
J Antimicrob Chemother; 1997 May; 39 Suppl A():69-73. PubMed ID: 9511067
[TBL] [Abstract][Full Text] [Related]
50. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.
Entenza JM; Drugeon H; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1995 Jul; 39(7):1419-24. PubMed ID: 7492078
[TBL] [Abstract][Full Text] [Related]
51. Use of streptogramin growth promoters in poultry and isolation of streptogramin-resistant Enterococcus faecium from humans.
Kieke AL; Borchardt MA; Kieke BA; Spencer SK; Vandermause MF; Smith KE; Jawahir SL; Belongia EA;
J Infect Dis; 2006 Nov; 194(9):1200-8. PubMed ID: 17041845
[TBL] [Abstract][Full Text] [Related]
52. Detection of quinupristin-dalfopristin resistance in methicillin-resistant Staphylococcus aureus in South India.
Kali A; Stephen S; Umadevi S; Kumar S
Indian J Pathol Microbiol; 2013; 56(1):73-4. PubMed ID: 23924572
[No Abstract] [Full Text] [Related]
53. Inducible clindamycin resistance in erythromycin-resistant, non-multiresistant, methicillin-resistant Staphylococcus aureus.
Munckhof WJ; Kleinschmidt SL; Schooneveldt JM
Pathology; 2004 Aug; 36(4):373-4. PubMed ID: 15370145
[No Abstract] [Full Text] [Related]
54. [Changes of methicillin-resistant Staphylococcus aureus (MRSA) phagotypes in Gdansk in 1990-1998].
Wiśniewska K; Piechowicz L; Galiński J
Med Dosw Mikrobiol; 2000; 52(4):333-40. PubMed ID: 11286175
[TBL] [Abstract][Full Text] [Related]
55. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis.
Mouton JW; Endtz HP; den Hollander JG; van den Braak N; Verbrugh HA
J Antimicrob Chemother; 1997 May; 39 Suppl A():75-80. PubMed ID: 9511068
[TBL] [Abstract][Full Text] [Related]
56. Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
Rybak MJ; Houlihan HH; Mercier RC; Kaatz GW
Antimicrob Agents Chemother; 1997 Jun; 41(6):1359-63. PubMed ID: 9174199
[TBL] [Abstract][Full Text] [Related]
57. Genetic characterization of erythromycin- and methicillin-resistant community-acquired Staphylococcus aureus isolated from children in Texas.
Bogdanovich T; Aydin N; Chavez-Bueno S; McCracken G; Bozdogan B; Appelbaum PC
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):231-3. PubMed ID: 17662559
[TBL] [Abstract][Full Text] [Related]
58. Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis.
Berthaud N; Huet Y; Diallo N; Desnottes JF
J Antimicrob Chemother; 1997 May; 39 Suppl A():93-8. PubMed ID: 9511071
[TBL] [Abstract][Full Text] [Related]
59. In vitro effectiveness of quinupristin/dalfopristin against Staphylococcus aureus strains.
Limoncu MH; Ermertcan S; Coşar G; Tünger O
Int J Antimicrob Agents; 2003 May; 21(5):493-5. PubMed ID: 12727087
[No Abstract] [Full Text] [Related]
60. In vitro combinations of five intravenous antibiotics with dalfopristin-quinupristin against Staphylococcus aureus in a 3-dimensional model.
Duez JM; Adochitei A; Péchinot A; Siebor E; Sixt N; Neuwirth C
J Chemother; 2008 Dec; 20(6):684-9. PubMed ID: 19129064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
